Synergy CHC Corp. (SNYR)
NASDAQ: SNYR · Real-Time Price · USD
2.598
-0.302 (-10.40%)
Mar 31, 2025, 12:04 PM EDT - Market open
Synergy CHC Revenue
In the year 2024, Synergy CHC had annual revenue of $34.83M, down -18.57%. Synergy CHC had revenue of $10.27M in the quarter ending December 31, 2024, a decrease of -22.29%.
Revenue (ttm)
$34.83M
Revenue Growth
-18.57%
P/S Ratio
0.63
Revenue / Employee
$967,618
Employees
36
Market Cap
22.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 34.83M | -7.94M | -18.57% |
| Dec 31, 2023 | 42.78M | 4.37M | 11.37% |
| Dec 31, 2022 | 38.41M | -1.82M | -4.51% |
| Dec 31, 2020 | 40.23M | 10.87M | 37.02% |
| Dec 31, 2019 | 29.36M | -4.47M | -13.21% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
SNYR News
- 5 months ago - U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names - Seeking Alpha
- 5 months ago - Synergy CHC Corp. Announces Closing of Initial Public Offering - GlobeNewsWire
- 5 months ago - Synergy CHC Corp. Prices $10.35 Million Initial Public Offering - GlobeNewsWire
- 3 years ago - Synergy CHC Pursues $69 Million U.S. Uplisting IPO - Seeking Alpha